Mouse IgG1 GOLD, Clone hksp OR Mouse IgG1 GOLD, Clone hksp84

Purified Recombinant Human CD47 (>98%)

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multistep process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 28°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ 70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 28°C

Clone B6H12 recognizes an epitope on human CD47.

CD47 is a 50 kD transmembrane protein receptor to the Ig superfamily that can manifest in four isoforms, differing only in the length of their cytoplasmic tail. CD47 is involved in various cellular processes including apoptosis, proliferation, adhesion, and migration, and plays a key role in immune and angiogenic responses. CD47 was first identified as a tumor antigen on human ovarian cancer and its expression has subsequently been found on multiple human tumor types such as acute myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), nonHodgkin’s lymphoma (NHL), multiple myeloma (MM), bladder cancer, and pediatric and adult brain tumors. CD47 interacts with membrane integrins, TSP1, and SIRPα. The CD47/SIRPα interaction results in the inhibition of phagocytosis by macrophages thus, allowing cancer cells to multiply unchecked. AntiCD47 antibody is a potential therapeutic target in a variety of cancers and for the treatment of pulmonary fibrosis. AntiCD47 antibody treatment not only facilitates macrophage phagocytosis of cancer, but also promotes the activation of cancerspecific lymphocytes by acting as a beacon, flagging cancer cells which now display altered proteins to which the immune system can react.

CD47 is expressed on leukocytes, platelets, erythrocytes, epithelial cells, endothelial cells, fibroblasts, and is overexpressed in ovarian cancer, as well as many different tumor cells.

Noncovalently associated with ß3 integrins CD51/CD61, CD41/CD61. Thrombospondin is a ligand for CD47.